Dark PoolEvent Monday, June 1, 2026Analyzed

Pacira BioSciences, Inc.

Bearish

Summary

This filing is NOT a Rule 506(b) or 506(c) Form D for capital raising. It is a Form DEFA14A — a notice regarding a definitive proxy material filing by Pacira BioSciences, Inc. (ticker: PCRX), a publicly traded company. No new capital was raised via this filing; the $65.0M figure appears to be a data entry error and does not represent proceeds from a private placement.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Full Analysis

### Executive Summary This filing is NOT a Rule 506(b) or 506(c) Form D for capital raising. It is a Form DEFA14A — a notice regarding a definitive proxy material filing by Pacira BioSciences, Inc. (ticker: PCRX), a publicly traded company. No new capital was raised via this filing; the $65.0M figure appears to be a data entry error and does not represent proceeds from a private placement. ### Investor Edge Ignore this filing for private placement intelligence. Sophisticated investors should check Pacira's definitive proxy statement filed under the same accession number for any shareholder proposals or board changes. ### Sector capital positioning No genuine private capital signal; the company is a public biopharmaceutical firm focused on non-opioid pain management, not a 'Technology Venture' as mislabeled. This filing does not reflect sector capital flows. ### Convergence Signals None. Filing is an SEC-required proxy disclosure unrelated to a capital raise, patents, contracts, or legislation. ### Key Takeaways - This is a proxy filing, not a private placement; $65.0M is not capital raised. - Data incorrectly classifies a public biopharma as 'Technology Venture' and 'Unknown' state. - No actionable intelligence for private capital investors from this filing. ### Risk Indicators & Flags MISCLASSIFIED FILING TYPE: DEFA14A is not a Form D. Incorrect industry label and capital amount suggest a data scraping or parsing error. No genuine regulatory or offering risk. ### Verification & References Verify the filer: SEC EDGAR search for '0001396814' shows Pacira BioSciences as a public company (CRX:PCRX). Accession 000162828026039589 is for a DEFA14A, not a Form D. The industry 'Technology Venture' is inconsistent with a biopharma company. The $65.0M 'Capital Raised' field is likely a data mapping error.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderJun 2, 2026

Promoting Advanced Artificial Intelligence Innovation and Security

This executive order directs multiple federal agencies to prioritize cybersecurity hardening of national security, Department of War, and civilian government systems within 30 days. It establishes a classified benchmarking process for 'covered frontier models' and a voluntary framework for AI developers to provide early access to such models to the government for cybersecurity purposes. It also creates an AI cybersecurity clearinghouse, expands cybersecurity hiring pathways, and directs enforcement against AI-enabled computer crimes.

presidential_memorandumMay 29, 2026

Approving Critical Position Pay Authority for National Security Investment Workforce

This memorandum authorizes the Office of Personnel Management to allocate up to 400 critical positions with pay up to $400,000 to recruit specialized talent for national security investment programs, focusing on critical minerals, advanced materials, and strategic supply chains. It directs OPM and OMB to oversee allocation and ensure pay is used only to recruit or retain exceptionally qualified individuals. The action aims to accelerate domestic mineral production and reduce foreign dependence.

Exec OrderMay 19, 2026

Integrating Financial Technology Innovation into Regulatory Frameworks

This executive order directs federal financial regulators to review and streamline regulations that hinder fintech innovation, particularly for small and emerging firms, and requests the Federal Reserve to evaluate expanding access to its payment accounts and services for non-bank and digital asset firms. It aims to reduce barriers to entry and encourage partnerships between fintech firms and traditional financial institutions, with specific deadlines for reviews and reports.